Theravance Biopharma (TBPH) Cash from Discontinued Operations (2021 - 2022)
Theravance Biopharma's (TBPH) quarterly Cash from Discontinued Operations came in at 178968000.0 in Q4 2022, down 6455.4% year-on-year from 2816000.0 in Q4 2021, and down 3335.75% on a QoQ basis from 5209000.0 in Q3 2022.
Theravance Biopharma (TBPH) Cash from Discontinued Operations (2021 - 2022) Analysis & Trends
Theravance Biopharma (TBPH) has 2 years of Cash from Discontinued Operations data on file, last reported at 178968000.0 in Q4 2022.
- On a quarterly basis, Cash from Discontinued Operations fell 6455.4% year-over-year to 178968000.0 in Q4 2022; TTM through Dec 2022 was 184566000.0, a N/A change from a year earlier, with the FY2022 full-year figure at 184566000.0, down 761.12% from the prior year.
- Cash from Discontinued Operations for Q4 2022 stood at 178968000.0, down from 5209000.0 in the prior quarter.
- Over the last five years, Cash from Discontinued Operations for TBPH reached as high as 2816000.0 in Q4 2021 and fell as low as 178968000.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Discontinued Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,831.58 Bn | 66,831.30 Bn | - | - |
| 2 | Nanobiotix | 1,916.61 Bn | 1,916.55 Bn | - | - |
| 3 | Akari Therapeutics | 976.78 Bn | 976.78 Bn | - | - |
| 4 | BeOne Medicines | 471.48 Bn | 466.69 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.78 Bn | 114.53 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.87 Bn | 61.12 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 63.06 Bn | 63.06 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.54 Bn | 34.53 Bn | 959.66 Mn | - |
| 10 | Theravance Biopharma | 865.33 Mn | 470.67 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | -178.97 Mn |
| Dec 31, 2022 | -178.97 Mn |
| Sep 30, 2022 | -5.21 Mn |
| Sep 30, 2022 | -5.21 Mn |
| Jun 30, 2022 | -1.00 Mn |
| Jun 30, 2022 | -1.00 Mn |
| Mar 31, 2022 | 615,000.00 |
| Mar 31, 2022 | 615,000.00 |
| Dec 31, 2021 | 2.82 Mn |
| Dec 31, 2021 | 2.82 Mn |